Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia
- PMID: 2665688
- DOI: 10.1001/archpsyc.1989.01810080075010
Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia
Abstract
Despite renewed interest in negative schizophrenic symptoms, the pathophysiological mechanisms involved in their development remain obscure. Although the cholinergic system has been implicated in schizophrenia, it has not been accorded a major role in current theories of pathophysiology. We present evidence from several lines of research that suggests that muscarinic hyperactivity may be implicated in the pathogenesis of negative schizophrenic symptoms. Specifically, cholinergic overdrive leads to a behavioral syndrome strikingly similar to the negative schizophrenic syndrome, anticholinergic agents may alleviate negative symptoms, schizophrenic patients with negative symptoms tend to "abuse" anticholinergics, and polysomnographic, neuroendocrine, and other pharmacological findings appear to be generally consistent with this hypothesis. The hypothesis is testable and is presented as a heuristic model that focuses on the dynamic interplay between cholinergic and dopaminergic systems in schizophrenia.
Similar articles
-
Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms.Schizophr Res. 1991 Jan-Feb;4(1):23-30. doi: 10.1016/0920-9964(91)90006-d. Schizophr Res. 1991. PMID: 2009253
-
The muscarinic system, cognition and schizophrenia.Neurosci Biobehav Rev. 2015 Aug;55:393-402. doi: 10.1016/j.neubiorev.2015.05.011. Epub 2015 May 21. Neurosci Biobehav Rev. 2015. PMID: 26003527 Review.
-
Cholinergic aspects of schizophrenia.Br J Psychiatry Suppl. 1999;(37):7-11. Br J Psychiatry Suppl. 1999. PMID: 10211133 Review.
-
Effect of anticholinergics on positive and negative symptoms in schizophrenia.Psychopharmacol Bull. 1992;28(3):297-302. Psychopharmacol Bull. 1992. PMID: 1480733
-
Sleep abnormalities in schizophrenia: cholinergic contribution.Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:294A-295A. doi: 10.1097/00002826-199201001-00152. Clin Neuropharmacol. 1992. PMID: 1498847 No abstract available.
Cited by
-
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.J Neural Transm (Vienna). 2008 Nov;115(11):1563-71. doi: 10.1007/s00702-008-0122-8. Epub 2008 Sep 20. J Neural Transm (Vienna). 2008. PMID: 18806925
-
Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86.Eur Arch Psychiatry Clin Neurosci. 1994;243(5):279-90. doi: 10.1007/BF02191586. Eur Arch Psychiatry Clin Neurosci. 1994. PMID: 8172943
-
Early Signs of Schizophrenia and Autonomic Nervous System Dysregulation: A Literature Review.Clin Neuropsychiatry. 2019 Apr;16(2):86-97. Clin Neuropsychiatry. 2019. PMID: 34908942 Free PMC article.
-
Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers.Psychopharmacology (Berl). 2015 May;232(9):1607-17. doi: 10.1007/s00213-014-3794-9. Epub 2014 Nov 7. Psychopharmacology (Berl). 2015. PMID: 25373869
-
Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.Behav Brain Res. 2011 Aug 10;221(2):527-36. doi: 10.1016/j.bbr.2010.02.022. Epub 2010 Feb 16. Behav Brain Res. 2011. PMID: 20170686 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical